THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

NCT07446257 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Resectable Hepatocellular Carcinoma

Interventions

DRUG: ateganosine
DRUG: Cadonilimab

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]
[object Object]